相关实验视频

Updated: Sep 18, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

精确指导PI3K路径抑制剂用于治疗固体恶性瘤的使用

Alexa E Schmitz¹, Shirsa Udgata¹, Katherine A Johnson²

¹McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin, Madison, WI 53705, USA.

|June 26, 2025

概括

在癌症中,酸丁醇-3-酶 (PI3K) / AKT / 哺乳动物目标拉巴胺素 (MTOR) 途径的过度激活是常见的. 本综述涵盖了针对固体瘤及其突变的PI3K/AKT/MTOR抑制剂.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

拉巴胺素 (MTOR) 途径的酸-3-酶 (PI3K) /AKT/哺乳动物点对于细胞功能至关重要,并且在各种癌症中经常过度激活.
准这种途径代表了一项重要的抗癌治疗策略,导致多种抑制剂的开发和FDA批准.

研究的目的:

在固体瘤中审查PI3K/AKT/MTOR信号通路内的治疗点.
总结PI3K,AKT和MTOR抑制剂对具有特定突变的癌症的当前临床应用.
要突出通过临床试验进展的新型抑制剂.

主要方法:

临床前和临床研究的文献综述.
对针对PI3K/AKT/MTOR信号的治疗策略的分析.
对FDA批准的抑制剂和新兴候选药物的检查.

主要成果:

过度激活PI3K/AKT/MTOR通路是许多恶性瘤的标志.
几种PI3K,AKT和MTOR抑制剂已被批准用于治疗具有激活突变的癌症 (例如PIK3CA,AKT1/2,MTOR).
针对这种途径的新抑制剂正在进入临床试验.

结论:

准PI3K/AKT/MTOR通路是固体瘤的验证的抗癌方法.
目前正在进行的新型抑制剂的研究和开发有望为PI3K/AKT/MTOR驱动癌症患者扩大治疗选择.
专注于特定途径突变的个性化医学方法是有效治疗的关键.

关键词:

在 AKT AKT 里面.在 MTOR 中,我们可以使用 MTOR.在PI3K中,PI3K是指PI3K.结肠直肠癌是什么意思有针对性的治疗.

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...